Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1.
Study Goal
The researchers aimed to determine whether dietary advanced glycation end products (AGEs) contribute to insulin resistance in type 2 diabetes and whether AGE restriction can improve insulin sensitivity by modulating AGER1 and SIRT1 pathways.
Results Summary
The study found that an AGE-restricted diet reduced insulin resistance, inflammatory markers, and oxidative stress in type 2 diabetic patients while restoring AGER1 and SIRT1 levels. AGE restriction also improved adiponectin levels and suppressed pro-inflammatory pathways in vitro.
Population
18 type 2 diabetic patients (age 61±4 years) and 18 healthy subjects (age 67±1.4 years).
Effective Dosage
Standard diet (>20 AGE Eq/day) vs. AGE-restricted diet (<10 AGE Eq/day).
Duration
4 months.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
AGE-restricted diet | decrease | Insulin | AGE-restricted type 2 diabetic patients | - | decreased | #1 |
AGE-restricted diet | decrease | homeostasis model assessment | AGE-restricted type 2 diabetic patients | - | decreased | #2 |
AGE-restricted diet | decrease | leptin | AGE-restricted type 2 diabetic patients | - | decreased | #3 |
AGE-restricted diet | decrease | tumor necrosis factor-α | AGE-restricted type 2 diabetic patients | - | decreased | #4 |
AGE-restricted diet | decrease | nuclear factor-κB p65 acetylation | AGE-restricted type 2 diabetic patients | - | decreased | #5 |
AGE-restricted diet | decrease | serum AGEs | AGE-restricted type 2 diabetic patients | - | decreased | #6 |
AGE-restricted diet | decrease | 8-isoprostanes | AGE-restricted type 2 diabetic patients | - | decreased | #7 |
AGE-restricted diet | increase | PMNC AGER1 mRNA levels | AGE-restricted type 2 diabetic patients | - | normalized | #8 |
AGE-restricted diet | increase | PMNC SIRT1 mRNA levels | AGE-restricted type 2 diabetic patients | - | normalized | #9 |
AGE-restricted diet | increase | PMNC AGER1 protein levels | AGE-restricted type 2 diabetic patients | - | normalized | #10 |
AGE-restricted diet | increase | PMNC SIRT1 protein levels | AGE-restricted type 2 diabetic patients | - | normalized | #11 |
AGE-restricted diet | increase | adiponectin | AGE-restricted type 2 diabetic patients | - | markedly increased | #12 |
AGEs | decrease | AGER1 levels | THP-1 cells | - | suppressed | #13 |
AGEs | decrease | SIRT-1 levels | THP-1 cells | - | suppressed | #14 |
AGEs | decrease | NAD+ levels | THP-1 cells | - | suppressed | #15 |
AGEs | decrease | suppressive effects on AGER1, SIRT-1, and NAD+ levels | AGER1-transduced (AGER1+) THP-1 cells | - | inhibited | #16 |
AGEs | increase | suppressive effects on AGER1, SIRT-1, and NAD+ levels | AGER1-silenced THP-1 cells | - | enhanced | #17 |
OBJECTIVE: Increased oxidative stress (OS) and impaired anti-OS defenses are important in the development and persistence of insulin resistance (IR). Several anti-inflammatory and cell-protective mechanisms, including advanced glycation end product (AGE) receptor-1 (AGER1) and sirtuin (silent mating-type information regulation 2 homolog) 1 (SIRT1) are suppressed in diabetes. Because basal OS in type 2 diabetic patients is influenced by the consumption of AGEs, we examined whether AGE consumption also affects IR and whether AGER1 and SIRT1 are involved. RESEARCH DESIGN AND METHODS: The study randomly assigned 36 subjects, 18 type 2 diabetic patients (age 61±4 years) and 18 healthy subjects (age 67±1.4 years), to a standard diet (>20 AGE equivalents [Eq]/day) or an isocaloric AGE-restricted diet (<10 AGE Eq/day) for 4 months. Circulating metabolic and inflammatory markers were assessed. Expression and activities of AGER1 and SIRT1 were examined in patients' peripheral blood mononuclear cells (PMNC) and in AGE-stimulated, AGER1-transduced (AGER1+), or AGER1-silenced human monocyte-like THP-1 cells. RESULTS: Insulin and homeostasis model assessment, leptin, tumor necrosis factor-α and nuclear factor-κB p65 acetylation, serum AGEs, and 8-isoprostanes decreased in AGE-restricted type 2 diabetic patients, whereas PMNC AGER1 and SIRT1 mRNA, and protein levels normalized and adiponectin markedly increased. AGEs suppressed AGER1, SIRT-1, and NAD+ levels in THP-1 cells. These effects were inhibited in AGER1+ but were enhanced in AGER1-silenced cells. CONCLUSIONS: Food-derived pro-oxidant AGEs may contribute to IR in clinical type 2 diabetes and suppress protective mechanisms, AGER1 and SIRT1. AGE restriction may preserve native defenses and insulin sensitivity by maintaining lower basal OS.